Blood Plasma Derivatives Market to grow at a CAGR of 6.47% during 2025 to 2035; Driven by Rising Demand for Plasma-Derived Therapies and Increasing Prevalence of Chronic Diseases

Blood Plasma Derivatives Market Highlights

Blood Plasma Derivatives Market Size was estimated at 43.3 USD Billion in 2024. The Blood Plasma Derivatives industry is projected to grow from 46.6 USD Billion in 2025 to 86.67 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.47% during the forecast period 2025 - 2035.

Test the market data and market information presented through more than 45 market data tables and figures spread over 80 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Blood Plasma Derivatives market Research Report –Global Forecast to 20230.”

Market Players:

Key players in Blood Plasma Derivatives market are: Grifols (Germany), SK Plasma (Korea), Fusion Healthcare (India), Baxter International Inc. (U.S), CSL Limited (Australia).Other players in this market are Octapharma AG (Germany), Biotest AG (Germany), Bain Capital (U.S).

Grifols is a leading producer of blood plasma derived protein therapies for patients who have rare genetic diseases. It has plasma donation 147 plasma donation centers across the world.

SK Plasma products include Liv- Gamma Inj. (human IgG solution) and ETBI Inj. (Plasma derived coagulation Factor VIII)

Fusion Healthcare manufactures a product named Genexglob (Normal human immunoglobulin Inj. 5g).

Regional Analysis

Globally, Blood Plasma Derivatives market consists of four regions North America, Europe, Asia-Pacific and Middle East and Africa. North America is segmented into countries into namely the U.S., Canada and Mexico. Europe market consists of countries namely U.K. France, Germany, Italy, Spain and Rest of Europe. Asia-Pacific market consists of countries namely India, China, Japan, Australia, Republic of Korea and Rest of Asia-Pacific and Middle East and Africa consists of countries namely United Arab Emirates, Saudi Arabia, Turkey and Rest of Middle East and Africa.

North America is expected to be the largest market for blood plasma derivatives. Increase in awareness regarding incidences of thrombocytosis and use of plasma derivatives to kill viruses causing infectious diseases favor the growth of market in this region. Demand for technological advancement in plasma derived products and extensive research in production of plasma derivatives initiate the growth of this market in Europe.

Asia-Pacific is expected to show fastest growth because of increase in prevalence of infectious diseases and emphasis on safe blood transfusion procedure. Countries in Middle East and Africa mostly export plasma derived products from the North American and European countries.

Global Blood Plasma Derivatives market has been segmented on the basis of type which includes albumin, anti-thrombin, intravenous immunoglobulin (IVIG), fresh frozen plasma (FFP) and others. Others types are Factor VII, Factor IX and Alpha 1 proteinase inhibitor concentrate.

On the basis on application the market is segmented into Hemophilia A, Hemophilia B, HIV, Hepatitis B, Hepatitis C, Thrombocytosis, and others. Other application includes Von Willebrand disease. End users include hospitals, clinics, diagnostic centers, blood transfusion centers and others.